Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Redcliffe Labs Announces Leadership Transition to Drive Healthcare Accessibility

Home
/
update
/
details

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

NextEdge Admin

19 Dec 2024

2 min 31 sec

Qualisure Diagnostics,Thyroid GuidePx®,thyroid cancer

OncoHelix, a leader in precision diagnostics, has partnered with Qualisure Diagnostics to launch the Thyroid GuidePx® test across Canada. This advanced genomic tool, designed for personalized treatment of papillary thyroid cancer (PTC), utilizes next-generation sequencing to improve patient outcomes by assessing tumor recurrence risk with unmatched precision.

PTC, the most common form of thyroid cancer, accounts for 80% of cases and is rising at a rate of 6% annually. While generally not life-threatening, PTC recurrence and treatment effects can significantly impact quality of life. Thyroid GuidePx® evaluates the expression of 82 genes associated with recurrence risks, enabling clinicians to distinguish low-risk cases and optimize treatment strategies ranging from active surveillance to surgery and adjuvant therapy. The test simplifies prognostication, outperforming the American Thyroid Association’s Clinical Risk Stratification System, reducing overtreatment, and enhancing patient care.

“This partnership underscores our dedication to equipping clinicians and patients with advanced diagnostic tools,” said Dr. Pinaki Bose, OncoHelix co-founder and EVP. “Thyroid GuidePx® exemplifies innovation in cancer diagnostics.”

Dr. Oliver Bathe, CEO of Qualisure Diagnostics, added, “Together, we’re advancing science and revolutionizing thyroid cancer care in Canada and beyond.”

Testing will be conducted at OncoHelix's clinically accredited laboratory, ensuring accuracy and reliability. This collaboration aligns with OncoHelix’s mission to transform cancer diagnostics and improve access to groundbreaking solutions.
OncoHelix specializes in precision diagnostic solutions, offering genomic and immunological profiling to support tailored care in Canada and globally.
Based in Calgary, Qualisure develops diagnostic tests that personalize cancer care and advance precision oncology as a global standard.